Treatment with the PCSK9* inhibitor alirocumab led to clinically meaningful reductions in low-density lipoprotein cholesterol (LDL-C) among adults with homozygous familial hypercholesterolaemia (HoFH), according to data from the ODYSSEY-HoFH** trial presented at the ACC.20/WCC Virtual meeting.
Individuals who reported a normal sleeping duration of 6–8 hours a night showed a lower chance of developing heart disease or stroke than those who slept for either shorter or longer durations, according to a secondary analysis of the Corinthia study presented at the ACC.20/WCC Virtual Meeting.
A substudy of the REDUCE-IT* trial – REDUCE-IT EPA** – presented at the ACC.20/WCC Virtual Meeting shows that the level of eicosapentaenoic acid (EPA) in the blood achieved from the consumption of icosapent ethyl (IE) – a pure, stable EPA ethyl ester – propelled the substantial reductions in cardiovascular (CV) event rates in statin-treated patients.
The use of nicotine e-cigarettes (ECs) along with counselling is more efficacious in aiding smoking cessation than counselling alone, according to 12-week results of a multicentre, randomized study presented at the American College of Cardiology 2020/World Congress of Cardiology (ACC.20/WCC) virtual meeting.
Rivaroxaban plus aspirin is effective in lowering the incidence of major adverse limb and cardiovascular (CV) events in patients with peripheral artery disease (PAD) undergoing lower-extremity revascularization, according to results of the VOYAGER-PAD trial presented at the American College of Cardiology and World Congress of Cardiology 2020 virtual meeting (ACC.20/WCC).
Vericiguat significantly reduces cardiovascular (CV) deaths and heart failure (HF)-related hospitalizations in patients with high-risk HF, according to results of the VICTORIA trial presented at the American College of Cardiology and World Congress of Cardiology virtual meeting (ACC.20/WCC).
A higher number of daily steps appears to be associated with lower home blood pressure (BP) in middle-aged individuals, according to the electronic Framingham Heart Study (eFHS) presented at the ACC.20/WCC Virtual Meeting.
Evinacumab, a fully human monoclonal antibody inhibitor of ANGPTL3, effectively lowers LDL-cholesterol (LDL-C) levels in patients with homozygous familial hypercholesterolaemia (HoFH) regardless of their LDL receptor (LDLR) function, according to results of a double-blind phase III trial presented at the American College of Cardiology and World Congress of Cardiology virtual meeting (ACC.20/WCC).
MitraClip NTR and XTR systems are effective and well tolerated for primary mitral regurgitation (MR), as shown in the prospective, multicentre, single-arm, international, post-marketing, real-world, observational EXPAND study presented at the American College of Cardiology 2020/World Congress of Cardiology (ACC.20/WCC) virtual meeting.
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.